New drug combo shows promise in Hard-to-Treat cancers

NCT ID NCT03829254

Recruiting now Disease control Sponsor: NuCana plc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called NUC-7738, given alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that haven't responded to other treatments. The goal is to find the safest dose and see if it can shrink tumors or slow cancer growth. About 135 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer lymphoma melanoma metastatic melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER LYMPHOMA MELANOMA SOLID TUMOR

Contacts and locations

Locations

Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital)
RECRUITING

Cambridge, CB2 0QQ, United Kingdom
Edinburgh Cancer Centre, Western General Hospital
RECRUITING

Edinburgh, EH4 2XU, United Kingdom
Freeman Hospital
RECRUITING

Newcastle, NE7 7DN, United Kingdom
Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital
RECRUITING

Preston, PR2 9HT, United Kingdom
Oxford University Hospitals NHS Foundation Trust
RECRUITING

Oxford, OX3 9DU, United Kingdom
The Beatson West of Scotland Cancer Centre
RECRUITING

Glasgow, G12 0TN, United Kingdom
The Christie NHS Foundation Trust
RECRUITING

Manchester, M20 4BX, United Kingdom
The Royal Marsden NHS Foundation Trust
RECRUITING

London, SW3 6JJ, United Kingdom
University College London Hospital
RECRUITING

London, NW1 2PG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.